65,437 trials
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up — 286 Participants
Osteoarthritis, Knee
Primary: Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of Treatment — -0.1361; -0.0442; -0.2261; -0.2000…
Seizures
Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…
Chronic Hepatitis C
Primary: Alanine Aminotransferase at Baseline — 109.2; 106.3; 110.6 IU/L
ADHD
Primary: The Effects of ADHD Medication Versus Placebo on Cotinine Levels — 180.7; 274.0 ng/ml — p=<0.05
Asthma
Primary: Respiratory Adverse Events Per Subject — 9.1; 3.4; 2.6; 2.2 Respiratory Adverse Events/Subject
Type 2 Diabetes
Primary: Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment — 5; 5; 0; 0 Participants
Ankylosing Spondylitis
Primary: Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria — 154; 35 participants — p=< 0.001
Parkinson Disease
Primary: Expert Panel Overall Assessment Following 2 Years on Drug — 34; 33; 81; 86 Participants
Myocardial Infarction · Heart Failure · Heart Enlargement
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi in mL/m2) at Day 90 Post Myocardial Infarction (MI) — 5.48; 5.09 mL/m2 — p=0.4239
Hypercholesterolemia
Primary: Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation — 257 participants
Heart Failure
Primary: Freedom From Left Ventricular Lead-related Complications — 100 percent of participants
Healthy
Primary: AUCτ Over a Dosing Interval (τ = 12 Hours) on Day 14 — 12090.998; 23472.1329; 30005.781; 50354.938 ng*h/mL
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Breast Neoplasms
Primary: Percent of Participants With Grade 3/4 Clinical Congestive Heart Failure (CHF) — 4.3; 0 Percentage of Participants